List of Tables

Table 1.1 Some Putative siRNA targets against cancer

Table 2.1 Drug Profile
Table 2.2 Major Modes of Liposomal Action and Related Applications
Table 2.3 Modes of Rnai Delivery and Potential Targets in Various Diseases
Table 2.4 Therapeutic intervention using siRNA
Table 2.5 siRNA – Clinical Trials
Table 2.6 Examples of siRNA delivery systems for treatment of cancers

Table 3.1 UV Spectrophotometric Absorbance of siRNA
Table 3.2 Accuracy of the Method
Table 3.3 Intraday Precision of the Method
Table 3.4 Interday Precision of the Method
Table 3.5 Volume of 0.01 M Na2EDTA Solution Required for Different Amounts of Calcium Chloride
Table 3.6 Acuracy of Method
Table 3.7 Intraday Precision of the Method
Table 3.8 Interday Precision of the Method
Table 3.9 Gel Electrophoresis – Relative Band Densities at Different siRNA Concentration

Table 4.1 Various Liposomal Formulations with Their Composition
Table 4.2 Selection of Process Parameters for Pre-formed Liposomes
Table 4.3 Selection of Process Parameters for Pre-Formed Liposomes
Table 4.4 Formulation Development of D Liposomes
Table 4.5 Formulation development of DD Liposomes
Table 4.6 Formulation development of DDH liposomes
Table 4.7 Formulation development of DDC Liposomes
Table 4.8 Formulation development of DDHC liposomes
Table 4.9 Formulation development of DDHCP liposomes
Table 4.10 Optimized Formulations
Table 4.11 Lyophilization Optimization
Table 4.12 Lyophilization Optimization
Table 4.13 Characterization of siRNA loaded liposomes
Table 4.14 siRNA Entrapment of Various Liposomes
Table 4.15 Effect of siRNA Complexation on Particle Size
Table 4.16 Effect of siRNA Complexation on Zeta Potential
Table 4.18 Methods for Calcium Phosphate Mediated siRNA Loading in Liposomes
Table 4.19 Various Variables and Responses Involved in Optimization
Table 4.20 Coded and Actual Values of the formulation parameters for step-1
Table 4.21 Coded and Actual Values of the formulation parameters for step-2
Table 4.22 Design Matrix for Calcium Chloride Loaded Liposome Optimization
Table 4.23 Summary of ANOVA results for Different Models
Table 4.24 ANOVA Table for Response Surface Quadratic Model
Table 4.25 Summary of ANOVA results for Quadratic Model
Table 4.26 Summary of ANOVA results for Different Models
Table 4.27 ANOVA table for Response Surface Quadratic Model
Table 4.28 Summary of ANOVA results for Quadratic Model
Table 4.29 Constraints Applied for Selection of Optimized Batch
Table 4.30 Optimized Batch Parameters Based on Desirability
Table 4.31 Predicted Responses of the Optimized Batch
Table 4.32 Experimental Confirmation of the Predicted Responses
Table 4.33 Effect of incubation time on siRNA Entrapment
Table 4.34 Effect of Incubation Temperature on siRNA Entrapment
Table 4.36 Summary of ANOVA results for Different Models
Table 4.37 ANOVA table for Response Surface Quadratic Model
Table 4.38 Summary of ANOVA results for Quadratic Model
Table 4.39 Summary of ANOVA results for Different Models
Table 4.40 ANOVA table for Response Surface Quadratic Model
Table 4.41 Summary of ANOVA results for Quadratic Model
Table 4.42 Constraints Applied for Selection of Optimized Batch
Table 4.43 Optimized Batch Parameters Based on Desirability
Table 4.44 Predicted Responses of the Optimized Batch
Table 4.45 Experimental Confirmation of the Predicted Responses
Table 4.46 Effect of RGD Levels on siRNA Entrapment and Particle Size
Table 4.47 Calcium Entrapment Efficiency of Optimized Liposomes
Table 4.48 Results of Assay of Various siRNA formulations
Table 4.49 siRNA Efficiency of Various RGD Grafted Liposomes (as Determined by Various Methods)
Table 4.50 Effect of incorporation of siRNA on Particle Size of Liposomes

Table 5.1 Cell-line Treatment Parameters for MTT Assay
Table 5.2 Cell-Line Treatment Parameters for Flow-Cytometry
Table 5.3 Cell-Line Treatment Parameters for Confocal Microscopy
Table 5.4 Details of Primers
Table 5.5 RNA to cDNA Conversion Parameters
Table 5.6 PCR Cycle Steps
Table 5.7 mRNA Quantification – Reaction Parameters
Table 5.8 RT-PCR Cycle Steps
Table 5.9 Viability of A549 Cells on Exposure to Cationic Liposomes
Table 5.10 Viability of H1299 Cells on Exposure to Cationic Liposomes
Table 5.11 Viability of H1299 Cells on Exposure to CPE Liposomes
Table 5.12 Viability of H1299 Cells on Exposure to Various CPE Liposomes
Table 5.13 Uptake of Liposomes in A549 Cells
Table 5.14 Uptake of Cationic Liposomes in A549 Cells
Table 5.15 Uptake of Liposomes in H1299 Cells
Table 5.16 Transfection in A549 Cells
Table 5.17 Transfection in H1299 Cells
Table 5.18 Chemosensitization of Gemcitabine HCl in A549 Cells
Table 5.19 Chemosensitization of Gemcitabine HCl in H1299 Cells
Table 5.20 IC50 values of Various Formulations with or without siRNA
Table 5.21 Change in IC50 of Gemcitabine HCl after Chemosensitization by RGD-DDHC Liposomes(2%)
Table 5.22 Change in IC50 of Gemcitabine HCl After Chemosensitization by RGD-CPE Liposomes(2%)
Table 5.23 Change in IC50 of Gemcitabine HClAfterChemosensitization by Lipofectamine 2000
Table 5.24 Comparison of Change in IC50 Value of Various Formulation
Table 5.25 Serum Stability of Liposomes
Table 5.26 Serum Stability of Naked siRNA
Table 5.27 In vitro Release in Serum at pH 7.4
Table 5.28 Haemolysis by Cationic Liposomes
Table 5.29 Haemolysis in CP liposomes
Table 5.30 Electrolyte Induced Flocculation of DDHC Liposomes
Table 5.31 Electrolyte Induced Flocculation of CPE Liposomes

Table 6.1 Sighting Study: Dosing protocol
Table 6.2 Results of Sighting Study
Table 6.3 MTD Study: Dosing Protocol
Table 6.4 Results for MTD study

Table 7.1 Stability Testing Data of RGD-DDHC Liposomes (2%)
Table 7.2 Stability Testing Data of RGD-CPE Liposomes (2%)